Efficacy and Safety of Ribociclib Plus Endocrine Therapy Versus Endocrine Therapy Alone in HR-Positive/HER2-Negative Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Background: Recent trials of ribociclib, a cyclin-dependent kinase inhibitor, have shown promising results in patients with hormone receptor-positive (HR+)/HER2-negative (HER2−) breast cancer. This meta-analysis evaluates the efficacy and safety of combining ribociclib with endocrine therapy (ET) ve...
Na minha lista:
| Principais autores: | , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
SAGE Publishing
2025-12-01
|
| coleção: | Clinical Medicine Insights: Oncology |
| Acesso em linha: | https://doi.org/10.1177/11795549251402955 |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|